1. Home
  2. SVRN vs KTTA Comparison

SVRN vs KTTA Comparison

Compare SVRN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SVRN

OceanPal Inc.

N/A

Current Price

$52.06

Market Cap

17.0M

ML Signal

N/A

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

N/A

Current Price

$0.48

Market Cap

18.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SVRN
KTTA
Founded
2021
2020
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.0M
18.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
SVRN
KTTA
Price
$52.06
$0.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
★ $3.00
AVG Volume (30 Days)
★ 204.3K
194.8K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.07
EPS
★ N/A
N/A
Revenue
N/A
★ $486,559.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3130.37
52 Week Low
$0.16
$0.28
52 Week High
$52.00
$2.06

Technical Indicators

Market Signals
Indicator
SVRN
KTTA
Relative Strength Index (RSI) 93.27 42.21
Support Level $4.03 $0.48
Resistance Level N/A $0.52
Average True Range (ATR) 5.34 0.04
MACD 4.13 -0.01
Stochastic Oscillator 87.01 27.91

Price Performance

Historical Comparison
SVRN
KTTA

About SVRN OceanPal Inc.

Svrn Inc operates in the digital asset and blockchain sector, with a focus on the NEAR Protocol. Its activities include managing a digital asset treasury comprising NEAR, promoting commercial adoption of NEAR-based products, and backing, building, and acquiring ventures that serve its mission.

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Share on Social Networks: